Provided by Tiger Trade Technology Pte. Ltd.

Amneal Pharmaceuticals, Inc.

17.69
-0.0950-0.53%
Volume:344.14K
Turnover:6.11M
Market Cap:5.64B
PE:36.78
High:17.93
Open:17.78
Low:17.65
Close:17.78
52wk High:19.26
52wk Low:9.20
Shares:319.00M
Float Shares:182.33M
Volume Ratio:0.34
T/O Rate:0.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.4808
EPS(LYR):0.2200
ROE:613.02%
ROA:8.60%
PB:170.83
PE(LYR):80.39

Loading ...

BRIEF-Kashiv Biosciences Agrees To Be Acquired By Amneal Pharmaceuticals To Create A Fully Integrated Global Biosimilar Leader

Reuters
·
Apr 22

BUZZ-Amneal rises as Kashiv BioSciences buy lifts biosimilar push, outlook

Reuters
·
Apr 22

Amneal Pharmaceuticals Shares up 3% Premarket After Annual Adj. Profit Forecast Raise, $1.1 Bln Deal to Acquire Kashiv Biosciences

THOMSON REUTERS
·
Apr 22

Amneal Pharmaceuticals' Q1 Adjusted Earnings, Revenue Rise; Agrees to Acquire in Kashiv BioSciences in Cash, Stock Deal

MT Newswires Live
·
Apr 22

Amneal agrees to acquire Kashiv BioSciences, deal seen closing in 2026

Reuters
·
Apr 22

Kashiv Biosciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader

THOMSON REUTERS
·
Apr 22

Amneal Pharma: Transaction Is Expected to Close in Second Half of 2026

THOMSON REUTERS
·
Apr 22

Amneal Pharmaceuticals to acquire Kashiv BioSciences

TIPRANKS
·
Apr 22

GUIDANCE: (AMRX) Amneal Pharmaceuticals Expects 2026 Revenue Range $3.05B - $3.15B, vs. FactSet Est of $3.1B

MT Newswires Live
·
Apr 22

BRIEF-Amneal Pharmaceuticals Outlook FY Revenue USD 3,050-3,150 Million Vs. IBES Estimate USD 3,097 Million

Reuters
·
Apr 22

Amneal Pharma - Deal Expected to Deliver $400 Mln-$500 Mln in Financial Benefits

THOMSON REUTERS
·
Apr 22

Amneal Pharmaceuticals Outlook FY Adjusted Ebitda USD 740-770 Million

THOMSON REUTERS
·
Apr 22

Amneal Pharma - Expects Over 12 Commercial Biosimilars and 20 Pipeline Products by 2030

THOMSON REUTERS
·
Apr 22

Amneal Pharmaceuticals Inc FY2026 Shr View $0.99, REV View $3.10 Bln -- Lseg Ibes Data

THOMSON REUTERS
·
Apr 22

Amneal Pharmaceuticals Outlook FY Operating Cash Flow USD 350-400 Million

THOMSON REUTERS
·
Apr 22

Amneal Pharmaceuticals Outlook FY Revenue USD 3,050-3,150 Million VS. Ibes Estimate USD 3,097 Million

THOMSON REUTERS
·
Apr 22

Amneal Pharmaceuticals Outlook FY Capex USD 110 Million

THOMSON REUTERS
·
Apr 22

Amneal Pharma: Deal Expected to Provide Substantial Financial Synergies Through Elimination of Upcoming Milestone & Royalty Obligations Through 2030

THOMSON REUTERS
·
Apr 22

Amneal Pharma - Q1 2026 Preliminary Consolidated Net Revenue $723 Mln, up 4% Year Over Year

THOMSON REUTERS
·
Apr 22

Amneal Pharma - Raises 2026 Adj Diluted EPS Guidance to $0.95-$1.05

THOMSON REUTERS
·
Apr 22